CAMP4 Therapeutics opened lower at $4.19, compared with its previous close of $4.20. In the last trading session, the stock traded between $3.98 and $4.30. It showed a downward intraday trend.
An investment of $100 made 5 years ago in CAMP4 Therapeutics is now worth
$ 1.69
Resulting in a loss of
$ 98.31 (98.31%)
Note: Past profits do not guarantee future returns.
Rating from 8 Analysts
Today's Change
$-0.07 (-1.67%)
Day High
$4.30
Day Low
$3.98
Day Open
$4.19
Prev Close
$4.20
Volume
44,426
1W Return
10.25%
1M Return
12.56%
3M Return
-1.01%
6M Return
-6.14%
1Y Return
0.00%
Market Cap ($ Mn)
259
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-153.99%
ROCE
-118.05%
EPS (TTM)
-
1 Week
10.25%
1 Month
12.56%
3 Months
-1.01%
6 Months
-6.14%
9 Months
-11.75%
Needham initiates Buy rating on Camp4 Therapeutics with $8 target
Needham initiated coverage on Camp4 Therapeutics with a Buy rating. Analyst Joseph Stringer set a price target of $8. The action represents the start of formal research coverage.
28 days agoCAMP4 Therapeutics to host virtual analyst day on September 28
CAMP4 Therapeutics to host virtual Analyst Day on September 28, 2026. Session scheduled from 12:00 – 1:30 PM ET with executive leadership. Focus on CMP-002 data for SYNGAP1-related disorder treatment. Patient advocates and KOL to participate in Q&A.
2mo agoCAMP4 Q2 Loss Widens to $33.5M; EPS Misses Estimates
CAMP4 Therapeutics reported a Q2 net loss of $33.5 million, driven by a $20.9 million non-cash derivative loss, causing EPS of $(0.58) to miss estimates. Revenue of $1.78 million missed the $1.90 million consensus but rose 18.8% YoY. The company raised $50.1 million post-quarter and maintains liquidity through 2028.
3mo agoCAMP4 Therapeutics secures TGA clearance for CMP-002 trial, enabling $50 million raise
CAMP4 Therapeutics Corporation announced on July 27, 2026, that it has received clearance from Australia’s TGA and HREC to start Phase 1/2 trials for CMP-002, a treatment for SYNGAP1-related disorder. This regulatory achievement enables the company to raise up to $50 million via the second closing of a private placement announced in September 2025, supporting its RNA-targeting therapeutic pipeline.
3mo agoCAMP4 Therapeutics grants inducement stock options to new employee
CAMP4 Therapeutics Corporation granted non-qualified stock options for 8,000 shares to a new employee under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $4.21 per share, a ten-year term, and vest over four years. The grant aligns with the company’s 2026 Inducement Plan to incentivize new talent.
3mo agoCAMP4 Therapeutics grants inducement options to new hires
CAMP4 Therapeutics Corporation granted non-qualified stock options for 39,000 shares to three new employees under Nasdaq Listing Rule 5635(c)(4). The options, priced at $3.96 per share, vest over four years with a ten-year term.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in CAMP4 Therapeutics is now worth
$ 1.69
Resulting in a loss of
$ 98.31 (98.31%)
Note: Past profits do not guarantee future returns.
